Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Kazi, Julhash U. LU orcid ; Kabir, Nuzhat N and Rönnstrand, Lars LU orcid (2013) In Medical Oncology 30(4). p.757-757
Abstract
Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes. This family of proteins plays critical roles in signal transduction which results in cell proliferation, survival, differentiation and apoptosis. Due to differential subcellular localization and tissue distribution, each member displays distinct signaling characteristics. In this review, we have summarized the roles of PKC family members in chronic lymphocytic leukemia (CLL). CLL is a heterogeneous hematological disorder with survival ranging from months to decades. PKC isoforms are differentially expressed in CLL and play critical roles in CLL pathogenesis. Thus, isoform-specific PKC inhibitors may be an attractive option for CLL... (More)
Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes. This family of proteins plays critical roles in signal transduction which results in cell proliferation, survival, differentiation and apoptosis. Due to differential subcellular localization and tissue distribution, each member displays distinct signaling characteristics. In this review, we have summarized the roles of PKC family members in chronic lymphocytic leukemia (CLL). CLL is a heterogeneous hematological disorder with survival ranging from months to decades. PKC isoforms are differentially expressed in CLL and play critical roles in CLL pathogenesis. Thus, isoform-specific PKC inhibitors may be an attractive option for CLL treatment. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Medical Oncology
volume
30
issue
4
pages
757 - 757
publisher
Humana Press
external identifiers
  • wos:000327858800006
  • pmid:24174318
  • scopus:84886445247
  • pmid:24174318
ISSN
1559-131X
DOI
10.1007/s12032-013-0757-7
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Experimental Clinical Chemistry (013016010)
id
fc5015fa-1588-403c-a08b-a8902651b383 (old id 4179969)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24174318?dopt=Abstract
date added to LUP
2016-04-01 10:13:05
date last changed
2022-04-27 19:49:11
@article{fc5015fa-1588-403c-a08b-a8902651b383,
  abstract     = {{Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes. This family of proteins plays critical roles in signal transduction which results in cell proliferation, survival, differentiation and apoptosis. Due to differential subcellular localization and tissue distribution, each member displays distinct signaling characteristics. In this review, we have summarized the roles of PKC family members in chronic lymphocytic leukemia (CLL). CLL is a heterogeneous hematological disorder with survival ranging from months to decades. PKC isoforms are differentially expressed in CLL and play critical roles in CLL pathogenesis. Thus, isoform-specific PKC inhibitors may be an attractive option for CLL treatment.}},
  author       = {{Kazi, Julhash U. and Kabir, Nuzhat N and Rönnstrand, Lars}},
  issn         = {{1559-131X}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{757--757}},
  publisher    = {{Humana Press}},
  series       = {{Medical Oncology}},
  title        = {{Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.}},
  url          = {{https://lup.lub.lu.se/search/files/1659083/4497691.pdf}},
  doi          = {{10.1007/s12032-013-0757-7}},
  volume       = {{30}},
  year         = {{2013}},
}